1-3 of 3
Steffen Aulwurm, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD
Journal: Blood
Blood (2013) 122 (21): 1454.
https://doi.org/10.1182/blood.V122.21.1454.1454
Published: 2013
Journal Articles

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

Ursula J.E. Seidel, Ludger Grosse-Hovest, PhD, Patrick Schlegel, MD, Martin Hofmann, Friedhelm R. Schuster, MD, Kai-Erik Witte, Steffen Aulwurm, PhD, Rouwen Teltschik, Elwira Pyz, PhD, Hans-Georg Rammensee, Gundram Jung, MD, Rupert Handgretinger, Prof., Peter Lang, MD
Journal: Blood
Blood (2013) 122 (21): 3905.
https://doi.org/10.1182/blood.V122.21.3905.3905
Published: 2013
Journal Articles

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Peter Lang, MD, Heiko-Manuel Teltschik, MD, Patrick Schlegel, MD, Ursula Seidel, Ludger Grosse-Hovest, PhD, Steffen Aulwurm, PhD, Martin Hofmann, Rouwen Teltschik, Kai Witte, MD, Hans-Georg Rammensee, Prof., Gundram Jung, MD, Rupert Handgretinger, MD
Journal: Blood
Blood (2012) 120 (21): 581.
https://doi.org/10.1182/blood.V120.21.581.581
Published: 2012